TVGN

Tevogen Bio Holdings Inc. (TVGN) - Q2 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2025. Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company developing off-the-shelf, precision T cell therapies (ExacTcell technology) for infectious diseases and cancers. The company's lead candidate, TVGN 489, has completed a Phase 1 proof-of-concept trial for high-risk COVID-19 patients. The company operates as a single segment and has not yet generated product revenue.

Key Financial Metrics

Note: Net loss for the six months ended June 30, 2025, was primarily driven by $10.53 million in non-cash stock-based compensation expense.

Material Changes vs. Prior Period

• Expense Reduction: Total operating expenses decreased significantly from $38.12 million in the six months ended June 30, 2024, to $15.80 million in the same period in 2025. This reduction is largely attributable to a decrease in non-cash stock-based compensation (from $30.48 million to $10.53 million) and the absence of $7.50 million in merger transaction costs recorded in 2024.
• Net Income/Loss Volatility: The company reported a net income of $1.60 million for the six months ended June 30, 2024, driven by a $48.47 million non-cash gain on the change in fair value of convertible promissory notes. In contrast, the six months ended June 30, 2025, resulted in a net loss of $15.87 million.
• Liquidity Position: Cash balances decreased from $1.28 million at December 31, 2024, to $0.69 million at June 30, 2025, reflecting a net cash outflow of $6.50 million from operating activities.
• Debt Utilization: The company drew an additional $3.40 million under its Loan Agreement during the first half of 2025, bringing the outstanding balance to $4.40 million.

Outlook, Risks, and Unusual Items

• Liquidity and Funding: Management believes current cash, combined with subsequent funding (including $2.53 million net proceeds from an "at-the-market" sales agreement and $1.0 million in grants received in August 2025), plus $24.0 million remaining available under the Loan Agreement and $7.0 million in committed grants, will fund operations for at least the next 12 months.
• Capital Raising: The company entered into a Sales Agreement on July 3, 2025, allowing for the sale of up to $50.0 million of common stock. Between July 3 and August 13, 2025, approximately 2.3 million shares were sold for gross proceeds of $2.60 million.
• Related Party Transactions: Significant financing and operational support comes from related parties, including The Patel Family (Loan Agreement, Preferred Stock purchases) and KRHP LLC (grants). The company is in default on $1.65 million in Notes Payable assumed in the merger, though no immediate transfer of shares or cash is required by default provisions.
• Internal Controls: Management concluded that disclosure controls and procedures were not effective as of June 30, 2025, due to material weaknesses in internal control over financial reporting.
• Operational Status: The company does not plan to initiate new clinical trials until additional funding is received.

Investor Verification Checklist

• Runway Validation: Verify the timing and certainty of the remaining $7.0 million grant commitment from KRHP and the ability to draw the full $24.0 million under the Loan Agreement.
• Debt Default Status: Confirm the status of the $1.65 million Notes Payable default and any potential acceleration clauses or creditor actions.
• Stock-Based Compensation: Assess the impact of the $89.0 million in unrecognized stock-based compensation costs (vesting over 8.8 years) on future earnings and cash flow.
• Internal Controls: Review the remediation plan for the material weaknesses in internal controls over financial reporting.
• Dilution Risk: Evaluate the potential dilution from the $50.0 million Sales Agreement, the Loan Agreement's purchase options (exercisable if stock price reaches $10.00), and the conversion of Series A and Series C Preferred Stock.